Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Intellia Therapeutics ( (NTLA) ).
On April 7, 2026, Intellia Therapeutics, Inc.’s board of directors adopted amendments to its by-laws to create a Fourth Amended and Restated By-law framework, following a recommendation from its nominating and corporate governance committee. The new provisions allow shareholders to cure facially apparent deficiencies in timely nomination or proposal notices and require the company to alert shareholders to such deficiencies.
The amended by-laws also designate the federal district courts of the United States as the exclusive forum for resolving complaints arising under the Securities Act of 1933 and the Securities Exchange Act of 1934, unless the company agrees in writing to an alternative venue. These changes are expected to streamline shareholder proposal procedures and concentrate securities-related litigation in federal courts, potentially providing greater predictability for the company and its investors.
The most recent analyst rating on (NTLA) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.
Spark’s Take on NTLA Stock
According to Spark, TipRanks’ AI Analyst, NTLA is a Neutral.
Overall score reflects weak fundamentals typical of a development-stage biotech (persistent losses and cash burn) as the primary constraint. Offsetting this are improving technicals and a moderately positive clinical/regulatory outlook (upcoming pivotal lonvo-z catalysts and MAGNITUDE restart), while valuation support is limited given negative earnings and no dividend.
To see Spark’s full report on NTLA stock, click here.
More about Intellia Therapeutics
Intellia Therapeutics, Inc. operates in the biotechnology sector, focusing on developing therapeutic products based on advanced genetic and molecular technologies. The company’s activities are overseen by a board of directors that sets corporate governance policies for its publicly traded operations and shareholder relations.
Average Trading Volume: 4,595,213
Technical Sentiment Signal: Hold
Current Market Cap: $1.63B
Learn more about NTLA stock on TipRanks’ Stock Analysis page.